Multimodal Treatment of Pleural Mesothelioma after the MARS-2 trial: Will We Change Our Ways?
All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.
Moderators
Boris Sepesi, MD
Ian Bostock, MD, MS
Presentations
- The New IASLC TNM Pleural Mesothelioma Staging and Its Effect on Treatment Options
Valerie Rusch, MD
- The Role of Pleurectomy and Decortication in Pleural Mesothelioma: How I Do It
Andrea Wolf, MD, MPH
- Novel Perioperative Analgesia Modalities During Pleurectomy and Decortication for Pleural Mesothelioma
Jeffrey B. Velotta, MD, FACS
Disclosure(s): Asparaglue: Consultant (Ongoing)
- Panel Discussion
- Updated Post-Recurrence Survival Outcomes in Patients Undergoing Pleurectomy/Decortication for Pleural Mesothelioma
Akifumi Nakamura, PhD, MD
- Prolonged Survival is Possible in Mesothelioma Patients Managed Non-Operatively: A National Cancer Database Analysis
Peter L. Zhan, MD
- Neoadjuvant Immunotherapy in the Treatment of Pleural Mesothelioma
Bryan M. Burt, MD
Disclosure(s): Bayou Surgical, Inc: Owner/Co-Owner Founder/Co-Founder (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), This is a startup company that I founded which is commercializing a device for minimally invasive surgery (Ongoing)
- Adjuvant Systemic and Immunotherapy Options in the Treatment of Pleural Mesothelioma
Jennifer Marie Suga, MD, MPH
Disclosure(s): Astrazeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Strata Oncology: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
- Panel Discussion
Available Credit
- 1.50 ABS Accredited CME
- 1.50 ABTS Accredited CME
- 1.50 AMA PRA Category 1 Credit™
Price
Cost:
$0.00
All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.
Moderators
Boris Sepesi, MD
Ian Bostock, MD, MS
Presentations
- The New IASLC TNM Pleural Mesothelioma Staging and Its Effect on Treatment Options
Valerie Rusch, MD
- The Role of Pleurectomy and Decortication in Pleural Mesothelioma: How I Do It
Andrea Wolf, MD, MPH
- Novel Perioperative Analgesia Modalities During Pleurectomy and Decortication for Pleural Mesothelioma
Jeffrey B. Velotta, MD, FACS
Disclosure(s): Asparaglue: Consultant (Ongoing)
- Panel Discussion
- Updated Post-Recurrence Survival Outcomes in Patients Undergoing Pleurectomy/Decortication for Pleural Mesothelioma
Akifumi Nakamura, PhD, MD
- Prolonged Survival is Possible in Mesothelioma Patients Managed Non-Operatively: A National Cancer Database Analysis
Peter L. Zhan, MD
- Neoadjuvant Immunotherapy in the Treatment of Pleural Mesothelioma
Bryan M. Burt, MD
Disclosure(s): Bayou Surgical, Inc: Owner/Co-Owner Founder/Co-Founder (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), This is a startup company that I founded which is commercializing a device for minimally invasive surgery (Ongoing)
- Adjuvant Systemic and Immunotherapy Options in the Treatment of Pleural Mesothelioma
Jennifer Marie Suga, MD, MPH
Disclosure(s): Astrazeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Strata Oncology: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
- Panel Discussion